Press Statements | Pfizer

You are here

Press Statements

03.25.2020

Pfizer Shares Safety Data on Azithromycin-Hydroxychloroquine Combination

03.02.2020

Pfizer Provides Comment on COVID-19 White House Meeting

01.23.2020

Pfizer Brings Three New Biosimilars to U.S. Patients at Substantial Discounts

11.15.2019

Pfizer Announces CHMP Opinion for XELJANZ® (tofacitinib) in the European Union Related to Ongoing Review of the Product

10.18.2019

Pfizer Statement on Vincristine Sulfate Injection, USP Supply in the United States

10.17.2019

Pfizer Statement on Results of Pay Equity Study and Opportunity Parity Among Colleagues Worldwide

09.17.2019

TrialSpark and Pfizer collaborating to improve speed and access to clinical trials

09.17.2019

Terry Bradshaw and Pfizer Educate Boomers About the Risks of Pneumococcal Pneumonia and the Importance of Vaccination

09.12.2019

Catalia Health and Pfizer collaborate to better understand patient journeys using artificial intelligence and via robot wellness coach

09.06.2019

Hospira, Inc., Issues A Voluntary Nationwide Recall for one lot of BACTERIOSTATIC WATER for Injection, USP, due to a Potential Lack of Sterility Assurance.

09.01.2019

Findings Released from NAXOS, a French Real-World Data Analysis and the Largest Real-World Data Analysis on Oral Anticoagulant Effectiveness and Safety in Europe Among Patients with Non-Valvular Atrial Fibrillation

08.14.2019

Pfizer Inc. Issues A Voluntary Nationwide Recall For 2 Lots of RELPAX® (eletriptan hydrobromide) 40 mg Tablets Due to Potential Microbiological Contamination of Non-Sterile Products

07.26.2019

Pfizer Statement on Update to XELJANZ® (tofacitinib) Prescribing Information in the United States

06.26.2019

Pfizer Responds to the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention’s Vote to Revise the Recommendation for Routine Use of Prevnar 13® for the Prevention of Pneumococcal Disease for Adults 65 Years or Older

05.17.2019

Pfizer confirms initiation of EU review of Tofacitinib with interim recommendations

04.26.2019

Pfizer Inc. Issues A Voluntary Nationwide Consumer Level Recall of One Lot of ThermaCare® Back Pain Therapy HeatWraps, up to 16HR pain relief, Due To Out of Specification Results for High Cell Temperature

03.18.2019

Hospira, Inc. Issues A Voluntary Nationwide Recall of 8.4% Sodium Bicarbonate Injection, USP Due To The Presence of Particulate Matter.

02.19.2019

Pfizer Announces Modification To Ongoing Tofacitinib FDA Post-Marketing Requirement Study In Patients With Rheumatoid Arthritis

11.26.2018

Pfizer Inc. Issues A Voluntary Nationwide Consumer Level Recall Of Six Lots Of ThermaCare® HeatWraps Due To Leaking Wraps with the Potential For Skin Injuries

11.16.2018

Pfizer Provides Transparency On Drug Prices In The U.S. 90 Percent Of Company’s Prices Will Remain Unchanged